Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas

NCT03409432 is registered in ClinicalTrials.gov with John Reneau as lead sponsor.

NCT NCT03409432
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03409432 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Brentuximab Vedotin and Lenalidomide in Relapsed and Refractory T-Cell Lymphomas
Lead sponsor
John Reneau
Phase
Phase 2
Overall status
Completed
Start date
March 16, 2018
Completion date
July 16, 2025
Enrollment
26 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphomatoid papulosis, primary cutaneous anaplastic large cell lymphoma, recurrent primary cutaneous t-cell non-hodgkin lymphoma, recurrent t-cell non-hodgkin lymphoma, refractory primary cutaneous t-cell non-hodgkin lymphoma, stage i cutaneous t-cell non-hodgkin lymphoma, stage ii cutaneous t-cell non-hodgkin lymphoma, stage iii cutaneous t-cell non-hodgkin lymphoma, stage iv cutaneous t-cell non-hodgkin lymphoma